Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, et al
The most common issues are gastrointestinal, concentrated during the dose escalation phase and typically improving after 48 weeks at a stable dose
It is hypothesized that Ipamorelin potentially increased the weights of fat pads in relation to body weight, which appeared to lead to an increase in relative body fat as quantified by dual energy X-ray absorptiometry (DEXA)
Semaglutide GLP-1 S, on the other hand, is studied within a much broader and more validated use case, with trial data reporting average body weight reductions exceeding 14% over 68 weeks a proof point that has made GLP-1 receptor agonists a far more established research category for metabolic and weight-related studies than growth hormone fragment peptides like AOD-9604